Alkihiro Yoshida (A Yoshida, Akihiro Yoshida)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Bariatric Surgery

Insulin Resistance

Top Venues

Diabetes, obesity & metabolism

Diabetic medicine : a journal of the British Diabetic Association

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 24 (12) (2022)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 23 (7) (2021)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Taeko Osawa, Kazuo Furukawa, Hiroshi Suzuki, Mayuko Harada Yamada, Shiro Tanaka, Kohei Kaku, Yasuhiro Matsubayashi
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 22 (6) (2020)
T Nojima, Y Matsubayashi, Alkihiro Yoshida, H Suganami, T Abe, M Ishizawa, K Fujihara, S Tanaka, K Kaku, Hirohito Sone
Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. Diabetic medicine : a journal of the British Diabetic Association 37 (8) (2020)
Yuichi Sato, Kiyohide Nunoi, Kohei Kaku, Alkihiro Yoshida, Hideki Suganami
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. Diabetes, obesity & metabolism 22 (2) (2019)